Zhang Xin, Li Qian, Liu Kuan, Shi Hong-Yun
Xin Zhang, Department of Radiotherapy, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China.
Qian Li, Department of Radiotherapy, Affiliated Hospital of Hebei University, Baoding 071000, Hebei, China.
Pak J Med Sci. 2024 Sep;40(8):1695-1701. doi: 10.12669/pjms.40.8.8770.
Retrospective study and analysis of the safety and efficacy of Rh-Rh-endostatinstatin combined with simultaneous radiotherapy in the treatment of cervical cancer.
A retrospective study was used to enroll cervical cancer patients who received Rh-endostatin combined with simultaneous radiotherapy (observation group) or radiotherapy alone (control group) from January 2019 to December 2022 in the Affiliated Hospital of Hebei University, and RECIST 1.1 criteria were used to evaluate the recent efficacy, and the WHO Adverse Reaction Scale for Anti-cancer Drugs to evaluate the toxic and side effects.
The difference between PR, SD, PD, ORR and DCR of the two groups was not statistically significant(>0.05), and the CR of the observation group was significantly higher than that of the control group(<0.05). The proportion of neutropenia, hypertension, arrhythmia, hemoglobin reduction in the observation group was significantly higher than that in the control group, and the proportion of nausea and vomiting was significantly lower than that in the control group(<0.05), and there was no significant difference in other adverse reactions(>0.05). After intervention, the CD3+, CD3-CD19+, CD16+CD56+, CEA, CY211 of both groups were significantly lower than before treatment(<0.05). After treatment, CD3+, CD3-CD19+, CD16+CD56+ were significantly higher in the observation group than in the control group, and WBC and PLT were significantly lower than before treatment(<0.05). The HPV conversion rate of the observation group was significantly higher than that of the control group(<0.05).
Our finding revealed that Rh-endostatinstatin combined with simultaneous radiotherapy showed better clinical outcomes and favorable toxic profile than that of radiotherapy alone in the treatment of cervical cancer.
回顾性研究与分析重组人血管内皮抑制素联合同步放疗治疗宫颈癌的安全性及疗效。
采用回顾性研究方法，选取2019年1月至2022年12月在河北大学附属医院接受重组人血管内皮抑制素联合同步放疗（观察组）或单纯放疗（对照组）的宫颈癌患者，采用RECIST 1.1标准评估近期疗效，采用世界卫生组织抗癌药物不良反应量表评估毒副作用。
两组的部分缓解（PR）、疾病稳定（SD）、疾病进展（PD）、客观缓解率（ORR）及疾病控制率（DCR）差异无统计学意义（>0.05），但观察组的完全缓解（CR）率显著高于对照组（<0.05）。观察组中性粒细胞减少、高血压、心律失常、血红蛋白降低的比例显著高于对照组，恶心呕吐的比例显著低于对照组（<0.05），其他不良反应差异无统计学意义（>0.05）。干预后，两组的CD3+、CD3-CD19+、CD16+CD56+、癌胚抗原（CEA）、细胞角蛋白19片段（CY211）均显著低于治疗前（<0.05）。治疗后，观察组的CD3+、CD3-CD19+、CD16+CD56+显著高于对照组，白细胞（WBC）和血小板（PLT）显著低于治疗前（<0.05）。观察组的人乳头瘤病毒（HPV）转阴率显著高于对照组（<0.05）。
我们的研究结果显示，重组人血管内皮抑制素联合同步放疗在治疗宫颈癌方面比单纯放疗具有更好的临床疗效和良好的毒性特征。
